716 related articles for article (PubMed ID: 18212742)
1. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.
Buzzai M; Jones RG; Amaravadi RK; Lum JJ; DeBerardinis RJ; Zhao F; Viollet B; Thompson CB
Cancer Res; 2007 Jul; 67(14):6745-52. PubMed ID: 17638885
[TBL] [Abstract][Full Text] [Related]
4. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
Gao QZ; Lu JJ; Liu ZD; Zhang H; Wang SM; Xu H
Asian J Androl; 2008 Jul; 10(4):635-41. PubMed ID: 18097517
[TBL] [Abstract][Full Text] [Related]
7. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
8. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
[TBL] [Abstract][Full Text] [Related]
9. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells.
Levitt RJ; Zhao Y; Blouin MJ; Pollak M
Cancer Lett; 2007 Oct; 255(2):300-6. PubMed ID: 17602833
[TBL] [Abstract][Full Text] [Related]
10. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Ben Sahra I; Regazzetti C; Robert G; Laurent K; Le Marchand-Brustel Y; Auberger P; Tanti JF; Giorgetti-Peraldi S; Bost F
Cancer Res; 2011 Jul; 71(13):4366-72. PubMed ID: 21540236
[TBL] [Abstract][Full Text] [Related]
11. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
12. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
[TBL] [Abstract][Full Text] [Related]
13. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.
Chang HL; Wu YC; Su JH; Yeh YT; Yuan SS
J Pharmacol Exp Ther; 2008 Jun; 325(3):841-9. PubMed ID: 18337475
[TBL] [Abstract][Full Text] [Related]
14. Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway.
Neuwirt H; Muller H; Cavarretta IT; Tiefenthaler M; Bartsch G; Konwalinka G; Culig Z
Int J Oncol; 2006 Aug; 29(2):503-12. PubMed ID: 16820895
[TBL] [Abstract][Full Text] [Related]
15. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Carcinogenesis; 2007 Jul; 28(7):1533-42. PubMed ID: 17389612
[TBL] [Abstract][Full Text] [Related]
16. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Zakikhani M; Dowling RJ; Sonenberg N; Pollak MN
Cancer Prev Res (Phila); 2008 Oct; 1(5):369-75. PubMed ID: 19138981
[TBL] [Abstract][Full Text] [Related]
17. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Zakikhani M; Dowling R; Fantus IG; Sonenberg N; Pollak M
Cancer Res; 2006 Nov; 66(21):10269-73. PubMed ID: 17062558
[TBL] [Abstract][Full Text] [Related]
18. The effect of chelerythrine on cell growth, apoptosis, and cell cycle in human normal and cancer cells in comparison with sanguinarine.
Malíková J; Zdarilová A; Hlobilková A; Ulrichová J
Cell Biol Toxicol; 2006 Nov; 22(6):439-53. PubMed ID: 16964588
[TBL] [Abstract][Full Text] [Related]
19. Chronic activation of AMP-activated kinase as a strategy for slowing aging.
McCarty MF
Med Hypotheses; 2004; 63(2):334-9. PubMed ID: 15236799
[TBL] [Abstract][Full Text] [Related]
20. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
